drugset / Trial / NCT04813653
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
Phase 1
Completed
3 enrolled
Tel-Aviv Sourasky Medical Center
Weizmann Institute of Science · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM).
Timeline
- Start
- 2021-04-18
- Primary completion
- 2025-03-05
- Completion
- 2025-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | — | — |
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | — | — |